Cue Biopharma (CUE) EBT (2017 - 2025)

Cue Biopharma has disclosed EBT across 9 years of filings, most recently posting $23.2 million for Q4 2025.

• EBT for Q4 2025 came in at $23.2 million, down 1.73% year-over-year; the trailing twelve-month figure through Dec 2025 was -$4.7 million (up 31.6% YoY), and the FY2025 annual result was -$4.7 million, up 32.45% from the prior year.
• EBT came in at $23.2 million for Q4 2025 at Cue Biopharma, up from -$7.4 million in the prior quarter.
• In the past five years, EBT ranged from a high of $23.6 million in Q4 2024 to a low of -$14.3 million in Q1 2022.
• The 5-year median for EBT is -$11.5 million (2022), against an average of -$7.9 million.
• Across the five-year window, EBT plunged 80.42% in 2022 and soared 282.69% in 2024, its largest moves.
• Cue Biopharma's EBT stood at -$7.9 million in 2021, then slumped by 80.42% to -$14.2 million in 2022, then grew by 9.18% to -$12.9 million in 2023, then jumped by 282.69% to $23.6 million in 2024, then fell by 1.73% to $23.2 million in 2025.
• The last three EBT figures came in at $23.2 million (Q4 2025), -$7.4 million (Q3 2025), and -$8.4 million (Q2 2025), per Business Quant data.